Home › Compare › DESTQ vs ABBV
DESTQ yields 373750000.00% · ABBV yields 3.06%● Live data
📍 DESTQ pulled ahead of the other in Year 1
Combined, DESTQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DESTQ + ABBV for your $10,000?
Destination Maternity Corporation designs and retails maternity apparel. As of September 17, 2019, the company operated 1,108 retail locations, including 474 stores in the United States, Canada, and Puerto Rico under the Motherhood Maternity, A Pea in the Pod, and Destination Maternity names; and 634 leased department locations in the United States and Puerto Rico. It also operated 184 international franchised locations comprising 9 stand-alone stores and 175 shop-in-shop locations in the Middle East, South Korea, Mexico, and Israel. The company's Motherhood Maternity brand serves the moderate priced portion of the maternity apparel business with stores located in regional malls, strip and power centers, and central business districts; and A Pea in the Pod brand offers an assortment of designer label maternity pieces with stores located in regional malls, lifestyle centers, and central business districts. Its Destination Maternity stores provide Motherhood Maternity and A Pea in the Pod products; and a line of maternity-related accessories, nursing products, health and fitness products, books, and body and nutritional products located in regional malls and lifestyle centers. The company also sells its merchandise on the Internet through its Websites, including Motherhood.com, APeaInThePod.com, DestinationMaternity.com, MotherhoodCanada.ca, and Amazon.com, as well as through Websites of retail partners, including Macys.com. The company was formerly known as Mothers Work, Inc. and changed its name to Destination Maternity Corporation in December 2008. Destination Maternity Corporation was founded in 1982 and is headquartered in Moorestown, New Jersey.
Full DESTQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.